Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Novopharm Biotech antibodies poised to enter phase I

Aug. 19, 1997

NeoRx and Janssen enter agreement for Avicidin

Aug. 14, 1997

ImClone Systems earns manufacturing milestone from Merck KGaA

Aug. 4, 1997

GnRH conjugate vaccines prepared at Merck & Co.

July 30, 1997

FDA advisory committee recommends approval of rituximab

July 28, 1997

Bristol-Myers Squibb licenses cancer vaccines from Progenics

July 18, 1997

Low-dose interferon alfa nears phase III for the treatment of Sjogren's syndrome

July 17, 1997

Maxamine enters phase III for malignant melanoma

July 15, 1997

Jenner Technologies reports results from phase I/II trial of prostate cancer vaccine

July 9, 1997

MDX-210 shows promise in advanced kidney and prostate cancer

July 1, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 30, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...